Other noncurrent assets Derivative Asset, Noncurrent Olumiant® Olumiant Olumiant [Member] Olumiant [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Work in process Inventory, Work in Process, Gross Repayments of long-term debt Repayments of Long-Term Debt Unrealized gross losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Stock repurchase program, remaining authorized amount Share Repurchase Program, Remaining Authorized, Amount Olanzapine Portfolio Olanzapine Portfolio [Member] Olanzapine Portfolio Cover [Abstract] Cover [Abstract] Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other current liabilities Other Liabilities, Current Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Trading Symbol Trading Symbol Fair Value Hedging Fair Value Hedging [Member] All Trading Arrangements All Trading Arrangements [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Defined Benefit Pension and Retiree Health Benefit Plans Amortization of retirement benefit items Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Non-NEOs Non-NEOs [Member] Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash dividend declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Accounts receivable, allowances Accounts Receivable, Allowance for Credit Loss, Current Common Stock (no par value) Common Class A [Member] Equity method investments Equity Method Investments Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Net investment gains (losses) on equity securities Net investment (gains) losses on equity securities (Note 7) Equity Securities, FV-NI, Gain (Loss) Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Basis of Presentation and Implementation of New Financial Accounting Standards Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] Financial Instruments Fair Value Disclosures [Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Net Investment Hedges Net Investment Hedging [Member] Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Other Performance Measure, Amount Other Performance Measure, Amount Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Other receivables Other Receivables, Net, Current 4.95% Notes Due 2063 4.95% Notes Due 2063 [Member] 4.95% Notes Due 2063 Gains on sale of product rights Gain (Loss) on Disposition of Intangible Assets 4.5% Notes Due 2029 4.5% Notes Due 2029 [Member] 4.5% Notes Due 2029 Cash Flow Hedging Cash Flow Hedging [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] U.S. UNITED STATES Service cost Defined Benefit Plan, Service Cost Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Retirement Plan Type [Axis] Retirement Plan Type [Axis] Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Common Stock in Treasury Treasury Stock, Common [Member] Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Schedule of Components of Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Buy USD Sell Euro Buy USD Sell Euro [Member] Buy USD Sell Euro [Member] Other Stockholders' Equity, Other Damages awarded, value Loss Contingency, Damages Awarded, Value Prepaid expenses Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Credit Facility 2028 Credit Facility 2028 [Member] Credit Facility 2028 Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Net periodic cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Total Debt Securities, Available-for-Sale Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Derivative asset, notional amount Derivative Asset, Notional Amount Insider Trading Policies and Procedures [Line Items] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Unfunded commitments to invest in venture capital funds, anticipated payment period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] 4.2% Notes Due 2029 4.2% Notes Due 2029 [Member] 4.2% Notes Due 2029 Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other current liabilities Business Combination, Contingent Consideration, Liability, Current Other neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Long-term income taxes payable Accrued Income Taxes, Noncurrent Trulicity® Trulicity [Member] Trulicity [Member] Asset Acquisition [Axis] Asset Acquisition [Axis] Fair value of securities in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Credit Facility [Domain] Credit Facility [Domain] Equity securities Equity Securities, FV-NI, Current Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Current Assets Assets, Current [Abstract] Goodwill Goodwill Daniel Skovronsky [Member] Daniel Skovronsky Potential achievements Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Terms or rights and obligations under collaborative arrangements. Ebglyss Ebglyss [Member] Ebglyss Investments in Equity and Debt Securities Fair Value of Financial Instruments, Policy [Policy Text Block] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Inventories Inventory Disclosure [Text Block] Basaglar® Basaglar Basaglar [Member] Basaglar [Member] Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Net Investment Hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Chugai Chugai [Member] Chugai Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Other financing activities, net Proceeds from (Payments for) Other Financing Activities Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Defined Benefit Pension Plans Pension Plan [Member] Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration] Security Exchange Name Security Exchange Name Schedule of the Contractual Maturities of Our Investments in Debt Securities Measured at Fair Value Investments Classified by Contractual Maturity Date [Table Text Block] Award Type Award Type [Axis] Corporate debt securities Corporate Debt Securities [Member] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Total (approximates replacement cost) Inventory, Gross Other, net of tax Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest Credit Facility 2025 Credit Facility 2025 [Member] Credit Facility 2025 Property and equipment, net of accumulated depreciation of $11,816.0 (2024) and $11,099.3 (2023) Property, Plant and Equipment, Net Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Noncontrolling interests Equity, Attributable to Noncontrolling Interest Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of the Fair Value of Available-for-Sale Securities in an Unrealized Gain or Loss Position Unrealized Gain (Loss) on Investments [Table Text Block] Expiration Date Trading Arrangement Expiration Date Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Proceeds from sale of product rights Proceeds from Sale of Intangible Assets Total Shareholder Return Amount Total Shareholder Return Amount Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued More Than 10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity 4.5% Notes Due 2027 4.5% Notes Due 2027 [Member] 4.5% Notes Due 2027 Taltz® Taltz [Member] Taltz [Member] 4.150% Notes Due 2027 4.150% Notes Due 2027 [Member] 4.150% Notes Due 2027 Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Europe Europe [Member] Verzenio® Verzenio [Member] Verzenio [Member] Cash paid for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Derivative liability, notional amount Derivative Liability, Notional Amount MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total Eli Lilly and Company shareholders' equity Equity, Attributable to Parent Senior Notes Due 2027, 2029, 2034, 2054, 2064 Senior Notes Due 2027, 2029, 2034, 2054, 2064 [Member] Senior Notes Due 2027, 2029, 2034, 2054, 2064 Proceeds from issuance of debt Proceeds from Issuance of Debt Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Less Than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Recognized actuarial gain (loss) Defined Benefit Plan, Amortization of Gain (Loss) Litigation Case [Axis] Litigation Case [Axis] Revenue recognized Disposal Group, Including Discontinued Operation, Revenue Interest expense Interest Expense, Nonoperating Hedging Designation [Domain] Hedging Designation [Domain] Other receivables Derivative Asset, Current Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-Term Investments Employee Benefit Trust Trust for Benefit of Employees [Member] Marketing, selling, and administrative Selling, General and Administrative Expense Proceeds from sales of and distributions from noncurrent investments Proceeds from Sale and Maturity of Other Investments Short-term borrowings and current maturities of long-term debt Debt, Current Other comprehensive income, net of tax (Note 11) Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Accounts receivable, net of allowances of $15.7 (2024) and $14.8 (2023) Accounts Receivable, after Allowance for Credit Loss, Current Net product revenue Product [Member] Long-term debt Long-term debt, including current portion Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Point Biopharma Global Inc Point Biopharma Global Inc [Member] Point Biopharma Global Inc Document Fiscal Period Focus Document Fiscal Period Focus Employee Litigation, July 2019 Ruling Employee Litigation, July 2019 Ruling [Member] Employee Litigation, July 2019 Ruling All Executive Categories All Executive Categories [Member] Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Other oncology Other Oncology [Member] Other Oncology [Member] Document Type Document Type Employee Litigation, July 2018 Ruling Employee Litigation, July 2018 Ruling [Member] Employee Litigation, July 2018 Ruling Derivative Contract [Domain] Derivative Contract [Domain] Commercial Paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Purchases of in-process research and development Payments to Acquire in Process Research and Development Cash and cash equivalents at January 1 Cash and Cash Equivalents at September 30 Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Hedged Fixed Rate Debt Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Schedule of Amounts Recorded for Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Contract liabilities Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Outside U.S. Non-US [Member] Accounts payable Accounts Payable, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Variable rate Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Acquisitions Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Short-term investments (Note 7) Short-Term Investments PEO Name PEO Name Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Actuarial losses, net Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Name Outstanding Recovery, Individual Name Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Increase to last-in, first-out (LIFO) cost Inventory, LIFO Reserve Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Acquisition date fair value of consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Accrued retirement benefits (Note 9) Liability, Defined Benefit Plan, Noncurrent Deferred tax assets Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Award Timing Predetermined Award Timing Predetermined [Flag] 5.0% Notes Due 2026 5.0% Notes Due 2026 [Member] 5.0% Notes Due 2026 Tyvyt® Tyvyt Tyvyt [Member] Tyvyt Retirement Benefits Retirement Benefits [Text Block] Brazil BRAZIL Swap Swiss Francs to U.S. Dollars Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Implementation of New Financial Accounting Standard New Accounting Pronouncements, Policy [Policy Text Block] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Erbitux® Erbitux [Member] Erbitux [Member] Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Net Unrealized Gains (Losses) on Cash Flow Hedges Net unrealized gains/losses on cash flow hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Asset impairment, restructuring, and other special charges (Note 5) Asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Morphic Holding, Inc. (Morphic) Morphic Holding, Inc [Member] Morphic Holding, Inc Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] China CHINA 0.500% Notes due 2033 .500% Notes Due 2033 [Member] .500% Notes Due 2033 [Member] Asset-backed securities Asset-Backed Securities [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Net income (loss) Total reclassifications, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income taxes (Note 8) Tax benefit Income Tax Expense (Benefit) Costs, expenses, and other Cost Of Sales, Operating Expenses, And Other-net Cost Of Sales, Operating Expenses, And Other-net Interest cost Defined Benefit Plan, Interest Cost Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Short-term investments Debt Securities, Available-for-Sale, Current Immunology Immunology [Member] Immunology [Member] Zepbound® Zepbound [Member] Zepbound Sell Chinese Yuan Sell Chinese Yuan [Member] Sell Chinese Yuan Other–net, (income) expense (Note 12) Other–net, (income) expense Nonoperating Income (Expense) Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Effective income tax rates, percentage Effective Income Tax Rate Reconciliation, Percent Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Business Acquisition [Line Items] Business Acquisition [Line Items] Versanis Bio, Inc. Versanis Bio, Inc [Member] Versanis Bio, Inc Research and development Research and Development Expense (Excluding Acquired in Process Cost) Total liabilities and equity Liabilities and Equity Other operating activities, net Other Operating Activities, Cash Flow Statement Cash dividends declared Dividends Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Employee compensation Employee-related Liabilities, Current Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Other current liabilities Derivative Liability, Current Schedule of Other–Net, (Income) Expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Other cardiometabolic health Other Cardiometabolic Health [Member] Other Cardiometabolic Health Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Legal Entity [Axis] Legal Entity [Axis] Dividends paid Payments of Dividends Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Individual: Individual [Axis] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Inventories (Note 6) Inventories Inventory, Net U.S. government and agency securities US Government Agencies Debt Securities [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Milestone payment received Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received Other Other Product, Total [Member] Other Product, Total [Member] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Additional cash proceeds Disposal Group, Including Discontinued Operation, Consideration Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Cost Portion at Other than Fair Value Measurement [Member] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Cash paid, net of cash acquired Business Combination, Consideration Transferred Liabilities and Equity Liabilities and Equity [Abstract] Offsetting Assets [Line Items] Offsetting Assets [Line Items] Schedule of Net Pension and Retiree Health (Benefit) Cost Schedule of Net Benefit Costs [Table Text Block] Description of Derivative Risk Management Derivatives, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Collaborative arrangement, rights and obligations percent (up to) Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Noncurrent investments Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Interest Rate Contracts Interest Rate Contract [Member] 6-10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] 4.875% Notes Due 2053 4.875% Notes Due 2053 [Member] 4.875% Notes Due 2053 Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Cyramza® Cyramza [Member] Cyramza [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Schedule of Fair Value Information, Liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Derivative Instrument [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Dividends payable Dividends Payable, Current Asset Acquisition [Table] Asset Acquisition [Table] Asset Impairment, Restructuring, and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Arrangement Duration Trading Arrangement Duration Other Other Product [Member] Other Product [Member] Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Cash Flow Hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Baqsimi Baqsimi [Member] Baqsimi Costs, expenses, and other: Costs and Expenses [Abstract] Net investment losses Gain (Loss) on Investments Cash paid for acquisitions, net of cash acquired Other Payments to Acquire Businesses Investments (Note 7) Noncurrent investments Long-Term Investments Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other securities Other Debt Obligations [Member] Benefit (expense) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt instrument, term Debt Instrument, Term All Individuals All Individuals [Member] PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other–net, (income) expense Other (income) expense Other Nonoperating Income (Expense) Retiree Health Benefit Plans Other Postretirement Benefits Plan [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Proceeds from sales of available-for-sale investments Proceeds From Sale Of Equity And Available For Sale Securities Proceeds From Sale Of Equity And Available For Sale Securities Disposal Group Name [Axis] Disposal Group Name [Axis] Unrealized gross gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Cost of common stock in treasury Treasury Stock, Common, Value Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Acquired IPR&D Charge Payments for Asset Acquisitions Payments for Asset Acquisitions Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total noncurrent liabilities Liabilities, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Average remaining maturity of foreign currency derivatives Average Remaining Maturity of Foreign Currency Derivatives Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Noncurrent Liabilities Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Accounts receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Line of Credit Line of Credit [Member] Net Unrealized Gains (Losses) on Available-For-Sale Securities Net unrealized gains/losses on available-for-sale securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Unfunded commitments to invest in venture capital funds Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Entity Emerging Growth Company Entity Emerging Growth Company 1.700% Notes due 2049 1.700% Notes Due 2049 [Member] 1.700% Notes due 2049 [Member] Entity Central Index Key Entity Central Index Key Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] DICE Therapeutics, Inc. DICE Therapeutics, Inc [Member] DICE Therapeutics, Inc Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Other immunology Other Immunology [Member] Other Immunology [Member] Japan JAPAN Schedule of Effects of Risk-Management Instruments Were Recognized in Other–Net, (Income) Expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Change in Accounting Estimate [Table] Change in Accounting Estimate [Table] 1.625% Notes due 2043 1.625% Notes Due 2043 [Member] 1.625% Notes Due 2043 Title Trading Arrangement, Individual Title Emergence Therapeutics AG Emergence Therapeutics [Member] Emergence Therapeutics Statement [Table] Statement [Table] Foreign Currency Translation Gains (Losses) Foreign currency translation gains/losses Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] City Area Code City Area Code Current Liabilities Liabilities, Current [Abstract] Other noncurrent liabilities Business Combination, Contingent Consideration, Liability Buy GBP Sell USD Buy GBP Sell USD [Member] Buy GBP Sell USD Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Purchases of short-term investments Payments to Acquire Short-Term Investments Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] 5.200% Notes Due 2064 5.200% Notes Due 2064 [Member] 5.200% Notes Due 2064 Purchases of common stock Payments for Repurchase of Common Stock Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Document Information [Line Items] Document Information [Line Items] Long-term debt Long-Term Debt, Excluding Current Maturities Losses expected to be reclassified in the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Acquired in-process research and development (IPR&D) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Income Taxes Income Tax Disclosure [Text Block] 0.625% Notes due 2031 .625% Notes Due 2031 [Member] .625% Notes due 2031 [Member] Earnings (loss) per share: Earnings Per Share [Abstract] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Sell Euro Sell Euro [Member] Sell Euro [Member] 1.125% Notes due 2051 1.125% Notes Due 2051 [Member] 1.125% Notes Due 2051 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net change in short-term borrowings Proceeds from (Repayments of) Short-Term Debt Net Cash Provided by (Used for) Financing Activities Net Cash Provided by (Used in) Financing Activities Orforglipron Orforglipron [Member] Orforglipron Underlying Securities Award Underlying Securities Amount Maturity Date 2025 Maturity Date 2025 [Member] Maturity Date 2025 Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Short-term commercial paper borrowings Commercial Paper Carrying Amount Reported Value Measurement [Member] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Fair Value as of Grant Date Award Grant Date Fair Value Other–Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Offsetting Assets [Table] Offsetting Assets [Table] Eli Lilly and Company Shareholders' Equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Other noncurrent liabilities Derivative Liability, Noncurrent 4.6% Notes Due 2034 4.6% Notes Due 2034 [Member] 4.6% Notes Due 2034 Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Forward-starting interest rate swaps Interest Rate Swap [Member] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Common stock Common Stock, Value, Issued Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Cash and cash equivalents (Note 7) Cash and Cash Equivalents, at Carrying Value Less: Business Combination, Cash Acquired [Abstract] Business Combination, Cash Acquired Emgality® Emgality [Member] Emgality [Member] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Raw materials and supplies Inventory, Raw Materials, Gross Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Sales rebates and discounts Sales Rebates And Discounts Sales Rebates And Discounts Finished products Inventory, Finished Goods, Gross Fair Value Measurement [Domain] Fair Value Measurement [Domain] Basic (in dollars per share) Earnings Per Share, Basic Purchases of property and equipment Payments to Acquire Other Property, Plant, and Equipment Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) Recognized Cash acquired Cash Acquired from Acquisition Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Foreign currency-denominated notes, designated as hedge Derivatives used in Net Investment Hedge, Net of Tax Cialis® Cialis [Member] Cialis [Member] Acquired in-process research and development (Note 3) Acquired in-process research and development Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Royalty Agreement Terms Royalty Agreement Terms [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Other securities Other Equity Securities [Member] Other Equity Securities [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Shares used in calculation of earnings (loss) per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Schedule of Significant Milestones and Revenue Recognized Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Cost of sales Cost of Goods and Services Sold Schedule of Fair Value Information, Assets Fair Value, Assets Measured on Recurring Basis [Table Text Block] Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and Contingencies (Note 10) Commitments and Contingencies Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Business Combinations Business Combinations Policy [Policy Text Block] Acquisitions Asset Acquisition [Text Block] Termination Date Trading Arrangement Termination Date Employee benefit trust Common Stock, Shares Held in Employee Trust Mortgage-backed securities Collateralized Mortgage-Backed Securities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Revenue (Note 2) Revenue Revenues Senior Notes Due 2026, 2033, 2053 And 2063 Senior Notes Due 2026, 2033, 2053 And 2063 [Member] Senior Notes Due 2026, 2033, 2053 And 2063 5.1% Notes Due 2064 5.1% Notes Due 2064 [Member] 5.1% Notes Due 2064 Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] 1.375% Notes due 2061 1.375% Notes Due 2061 [Member] 1.375% Notes Due 2061 Entity Address, City or Town Entity Address, City or Town Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Schedule of the Amounts Recognized for Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Net income (loss) Net income (loss) Net income Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC [Member] NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC Schedule of Fair Value, by Balance Sheet Grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Humulin® Humulin [Member] Humulin [Member] Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Humalog® Humalog [Member] Humalog [Member] Jardiance Jardiance Jardiance [Member] Jardiance [Member] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Revenue Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Forteo® Forteo [Member] Forteo [Member] Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Name Forgone Recovery, Individual Name Trajenta Trajenta (BI) [Member] Trajenta (BI) [Member] Document Period End Date Document Period End Date Schedule of Research and Development Assets Acquired Other than Through Business Combination Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation [Table Text Block] 5.0% Notes Due 2054 5.0% Notes Due 2054 [Member] 5.0% Notes Due 2054 Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Roche Roche [Member] Roche [Member] Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Insider Trading Arrangements [Line Items] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Buy U.S. Dollars Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Buy Euros Sell U.S. Dollars Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Foreign Exchange Contract Foreign Exchange Contract [Member] Transition Report Document Transition Report Quarterly Report Document Quarterly Report Swap U.S. Dollars to Euro Swap U.S. Dollars To Euro [Member] Swap U.S. Dollars To Euro [Member] 4.7% Notes Due 2033 4.7% Notes Due 2033 [Member] 4.7% Notes Due 2033 5.050% Notes Due 2054 5.050% Notes Due 2054 [Member] 5.050% Notes Due 2054 Purchases of noncurrent investments Payments to Acquire Other Investments Litigation Case Type [Domain] Litigation Case [Domain] 4.7% Notes Due 2034 4.7% Notes Due 2034 [Member] 4.7% Notes Due 2034 Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss (Note 11) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Maturity Date 2028 Maturity Date 2028 [Member] Maturity Date 2028 Asset Acquisition [Domain] Asset Acquisition [Domain] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Mounjaro® Mounjaro [Member] Mounjaro [Member] Document Information [Table] Document Information [Table] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Cardiometabolic Health Cardiometabolic Health [Member] Cardiometabolic Health Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Fair value of securities in an unrealized gain position Debt Securities, Available-For-Sale, Unrealized Gain Position Debt Securities, Available-For-Sale, Unrealized Gain Position Zyprexa Zyprexa [Member] Zyprexa [Member] Entity Filer Category Entity Filer Category Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name